According to this press release:
- Phase I cancer studies, trials that are conducted to determine the safety and maximum dose of a new agent, are under-reported in peer-reviewed journals - a trend that could ultimately delay scientific progress and negatively affect patient care, say researchers at The University of Texas M. D. Anderson Cancer Center in a new study out today (Mon., Aug, 22) online in Cancer...
"With all this new knowledge, the need to share information is paramount, now more than ever before," says Camacho, the study's senior author. "We, as clinicians and researchers, have a tremendous responsibility to not only investigate and discover new agents, but also to disseminate our discoveries - good and bad - to the medical community at large, to ensure the safety and well-being of our patients."
While medical meetings are another place to disseminate the information, Comacho, who is assistant professor of medicine in M. D. Anderson's Phase I Clinical Trials Program, says often these results are preliminary and subject to change after final analysis. Therefore, publishing in peer-reviewed scientific journals remains the "gold-standard" for sharing medical information.
